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Abstract. Three genomic regions, VP4 capsid, VP1 capsid and 3D RNA polymerase of human
enterovirus 71 (EV-71) and coxsackievirus A16 (CV-A16) were sequenced to understand the
evolution of these viruses in Malaysia. A total of 42 EV-71 and 36 CV-A16 isolates from 1997-
2008 were sequenced. Despite the presence of many EV-71 subgenotypes worldwide, only
subgenotypes B3, B4, B5, C1 and C2 were present in Malaysia. Importation of other
subgenotypes such as C3, C4/D and C5 from other countries was infrequent. For CV-A16, the
earlier subgenotype B1 was replaced by subgenotypes B2a and the recent B2c. Subgenotype
B2a was present throughout the study while B2c only emerged in 2005. No genetic signatures
could be attributed to viral virulence suggesting that host factors have a major role in
determining the outcome of infection. Only three EV-71 B3 isolates showed non-consistent
phylogeny in the 3D RNA polymerase region which indicated occurrence of recombination in
EV-71. High genetic diversity was observed in the Malaysian EV-71 but Malaysian CV-A16
showed low genetic diversity in the three genomic regions sequenced. EV-71 showed strong
purifying selection, but that occurred to a lesser extent in CV-A16.
INTRODUCTION
Human enterovirus 71 (EV-71) and
coxsackievirus A16 (CV-A16) are members
of the family of Picornaviridae, which also
include polioviruses, rhinoviruses and
echoviruses. Both viruses belong to the
species Human enterovirus A (HEV-A),
which includes other important human
pathogens such as coxsackieviruses A2-A8,
A10, A14, and A16. Both viruses are non-
enveloped, and their genomes are positive
single-stranded RNA of approximately 7400
bp in length. The genome is flanked by
untranslated regions in the 5’ and 3’, and
consists of VP4, VP2, VP3 and VP1 as the
structural proteins, and 2A, 2B, 2C, 3A, 3B,
3C and 3D as the non-structural proteins.
Both EV-71 and CV-A16 cause outbreaks
of hand, foot and mouth disease (HFMD) in
children. However, EV-71 can be potentially
fatal and cause serious neurological
diseases such as meningitis, encephalitis,
and acute flaccid paralysis. No severe CV-
A16 outbreaks have been reported, and
severe disease has only been reported
sporadically, including fatalities (Coopers
et al., 1989; Wang et al., 2004; Legay et al.,
2007) and one case of rhomboencephalitis
(Goto et al., 2009). CV-A16 was first isolated
in South Africa in 1951 (Pöyry et al., 1994)
and EV-71 was first isolated in California in
1969 (Schmidt et al., 1974). Over the last
decade, EV-71 epidemics have increased in
number and involved large numbers of
children in Asia, including Malaysia.
Fatalities have been observed in Bulgaria
(Chumakov et al., 1979), Hungary (Nagy et
al., 1982), Malaysia (Abu Bakar et al., 1999),
Taiwan (Huang et al., 1999) and China (Yang
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et al., 2009). Many European countries
such as Germany, Norway, United Kingdom,
Austria, Netherlands, France and Hungary
have also reported EV-71 cases (reviewed in
Chan et al., 2011). With the near-eradication
of poliovirus, EV-71 is the main enterovirus
posing a new global health threat in young
children.
Understanding of the epidemiology and
evolution of EV-71 and CV-A16 are important
for vaccine development and public health
control and prevention. Sequencing of VP4
and VP1 capsids for EV-71 and CV-A16 have
been reported for Malaysia (Abu Bakar et al.,
2000; Cardosa et al., 2003; Herrero et al.,
2003; Chua et al., 2007; Perera et al., 2007;
Yusof et al., 2011). However, very limited
data is available for the non-structural gene
regions such as 3D. Both viruses can
recombine at the non-structural proteins
with other HEV-A to form new variants with
altered virulence (Chan & Abu Bakar, 2004).
It has been reported that recombination is
one of the evolutionary driving forces of
EV-71 and CV-A16 (Chan & Abu Bakar, 2005;
Yoke-Fun & Abu Bakar, 2006). The frequency
of recombination in currently circulating
EV-71 and CV-A16 viruses is still not known.
Longitudinal epidemiological analyses
have only been reported for Taiwan and
Japan. There have been a few Malaysian
studies which covered peninsular Malaysia
and Sarawak, located in the Borneo Island
over a short period of time (Cardosa et al.,
2003; Herrero et al., 2003; Chua et al., 2007;
Perera et al., 2007; Yusof et al., 2011). There
are four EV-71 genotypes, A-D (Chan et al.,
2010) and two CV-A16 genotypes, A and B
(Perera et al., 2007; Zong et al., 2011). EV-71
genotype B can be further divided into B1-
B5, and subgenotype C can be divided into
C1-C5, and C4 which can also be considered
as genotype D (Chan et al., 2010). CV-A16
genotype B can be divided into B1, B2a, B2b
and B2c. At present, no Malaysian study has
analyzed the circulating genotypes of both
EV-71 and CV-A16, the two most important
causative agents of HFMD. We report here
the longitudinal epidemiological analyses of
EV-71 and CV-A16 isolated at our teaching
hospital in Kuala Lumpur over the last ten
years, and compare VP1, VP4 and 3D gene
sequences with other Malaysian isolates.
Comparison of genetic changes between
EV-71 and CV-A16 may also provide key
genetic signatures of virulence differences
between these two viruses.
MATERIALS AND METHODS
Clinical specimens
Clinical specimens were received by the
diagnostic virology laboratory in University
Malaya Medical Centre (UMMC) from 1997
to 2008. Specimens were collected from
patients with hand, foot and mouth disease
and neurological complications suspected
to be of enteroviral origin. The clinical
specimens included throat swabs, vesicle
swabs, stool, nasopharyngeal secretions
and cerebrospinal fluid. Virus isolation
was performed in Vero cells (ATCC CCL-81).
When cytopathic effects were observed,
immunofluorescence was performed with
Pan-Enterovirus Blend (Chemicon
International, Inc., Temecula, USA), and
confirmed using EV-71 and EV-71/CV-A16
specific monoclonal antibodies (Chemicon
International, Inc., Temecula, USA).
RNA extraction, reverse-transcription
PCR and sequencing
Viral RNA was extracted from 140 µl of viral
culture supernatants using the QIAamp Viral
RNA Mini Kit (Qiagen, Hilden, Germany),
and cDNA synthesis was performed using
SuperScript III Reverse Transcriptase
(Invitrogen, Carlsbad, USA) according to
the manufacturer’s instructions. PCR was
performed using GoTaq Flexi DNA
polymerase (Promega, Madison, USA) with
2 µl of cDNA. Each reaction was subjected
to 3 min of initial denaturation, followed
by 30 cycles of denaturing at 95°C for 1 min,
annealing between 42-60°C for 1 min
(depending on primer sets), and extension at
72°C for 1 min, and final extension of 72°C
for 5 min. Different primers were used to
amplify VP4, VP1 and 3D of EV-71 and CV-
A16 (Table 1). The amplicons were purified
with QIAquick gel purification kit (Qiagen,
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Hilden, Germany) and were sequenced with
ABI PRISM 377 DNA sequencer (Applied
Biosystems, California, USA).
Sequence identity analysis
Sequences were trimmed and assembled
using Geneious 5.0.3 (Biomatters Ltd.,
Auckland, New Zealand). After trimming,
EV-71 sequences of the complete VP4, partial
VP1 and partial 3D were 207 bp, 824 bp
(position in VP1, 42-867) and 537 bp (position
in 3D, 715-1020), respectively. For CV-A16,
the complete VP4 was 207 bp, complete VP1
was 891 bp, and partial 3D was 708 bp
(position in 3D, 639-1386). The amino acid
differences for all the genes were compared
with other genotypes.
Phylogenetic analysis
Multiple alignment was performed using
ClustalX 2.012 (Larkin et al., 2007). Phylo-
genetic trees were constructed using Kimura
two parameter and bootstraps of 1000
replicates were used to test the robustness of
the trees. The trees were displayed using
MEGA 5 (Tamura et al., 2011), with CV-A16/
G10 (CV-A16 prototype) as the outgroup for
EV-71 datasets, and BrCr (EV-71 prototype)
as the outgroup for the CV-A16 datasets.
Previously published sequences from
Malaysia and other reference sequences
were also downloaded for the analyses.
Selective pressure analysis
Selective pressure analysis was performed
using codon-based maximum likelihood
methods implemented in the Datamonkey
web server (Delport et al., 2010). Amino acids
were only selected when positively identified
by all three different codon-based maximum
likelihood methods, which were fixed effects
likelihood (FEL), internal branches FEL
(iFEL) and single likelihood ancestor
counting (SLAC). Random effects likelihood
(REL) was also used to determine positive
selection.
Nucleotide accession numbers
The sequences have been deposited into
GenBank with accession numbers JN248387-
JN248422 and JN316029-JN316208 (Table 2).
RESULTS
Isolation of EV-71 and CV-A16 in UMMC
From 1997 to 2008, 1248 samples from
patients suspected with enterovirus infection
were received by the virology laboratory at
UMMC, and of these, 203 (16.3%) samples
were culture-confirmed EV-71, and 48 (3.6%)
samples were culture-confirmed CV-A16. Of
these, 42 EV-71 and 36 CV-A16 isolates were
randomly chosen for amplification and
sequencing (Table 2). Two fatal EV-71 cases
were from the 1997 outbreak. All the CV-A16
sequences in the present study were from
mild HFMD cases.
Phylogenetic analysis of EV-71 and CV-
A16 in VP4 and VP1
EV-71 sequences from this study (n=42) were
aligned with other previously published EV-
71 sequences from Malaysia. Based on the
VP4 and VP1 trees, our isolates were grouped
in subgenotypes B3, B4, B5, C1 and C2.
Subgenotypes B3, B4, C1 and C2 were the
cause of the 1997 severe outbreak, while
subgenotypes B4 and C1 were co-circulating
during the 2000 and 2001 outbreaks.
Subgenotypes B3 and C2 were only
present in the 1997 outbreak and were not
isolated after that. Subgenotypes B4 and C1
also disappeared after 2001 and 2003,
respectively. Since then, subgenotype B5,
which first appeared in 2000, became the
subgenotype causing outbreaks in 2006.
This is the sole subgenotype currently
circulating in Malaysia (Figure 1, Figure 2).
The presence of Malaysian isolates in other
subgenotypes such as C4/D and C5 were only
seen in VP4, however this was not bootstrap
supported (Figure 1). The isolates clustered
according to the years and not according to
different geographical states in Malaysia.
Similarly, sequences of CV-A16 isolates
from this study (n=36) were aligned with
other previously published CV-A16 from
Malaysia. Based on the VP4 and VP1 trees,
our sequenced isolates were grouped into
subgenotypes B2a and B2c (Figure 3). A few
Sarawak isolates from 1998 and 2000 were
grouped in genotype B1. Subgenotype B2a
isolates were circulating throughout the
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study period and were dominant in 1997-2003,
2005 and 2007. Subgenotype B2c only
emerged after 2005 and was isolated again
in 2007 (Figure 3).
Non-consistent phylogeny observed at 3D
of EV-71 and CV-A16
The 3D regions for EV-71 and CV-A16 were
trimmed to 306 nucleotides for comparison
with other previously published Malaysian
isolates and other HEV-A isolates (Figure 4).
As previously reported, three EV-71 isolates
of subgenotype B3 were grouped with CV-
A16/G10 (Yoke-Fun & Abu Bakar, 2006).
Apart from this, other isolates were grouped
according to the subgenotypes previously
shown with VP1.
Comparison of genetic changes in EV-71
and CV-A16
Comparison of two viruses was performed
to identify possible genetic signatures that
contribute to virus virulence. Two fatal EV-
71 isolates were from subgenotypes B3 and
B4. Other non-fatal isolates from B3 and B4
also have very similar sequences to these
two fatal isolates. We found that EV-71 and
CV-A16 were genetically distinct and the
similarities at nucleotide and amino acid
levels were only 67-74% and 72-79% in VP4,
Figure 1. Phylogenetic tree of EV-71 VP4. The tree was drawn using VP4 gene sequences from this study
(?) and also other Malaysian sequences available in GenBank. The tree was outgrouped with CV-A16/
G10. All the subgenotypes and years of isolation of Malaysian isolates are labeled. Isolates from
subgenotype C4/D and C5 are underlined in black
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64-68% and 71-74% in VP1, and 74-83% and
93-98% in 3D, respectively.
The VP4, VP1 and 3D nucleotide and
amino acid similarities of EV-71 and CV-A16
isolates from this study are summarised in
Table 3. The EV-71 isolates showed greater
genetic diversity, while the CV-A16 isolates
were generally better conserved. For
example, for VP4, the genetic similarities
within EV-71 isolates were 78-100% and 89-
100% at nucleotide and amino acid levels,
respectively, while in CV-A16 isolates, the
genetic similarities were higher at 87-100%
and 98-100%, respectively.
The amino acids of different genotypes
for the three genomic regions, VP4, VP1 and
3D were compared (Figure 5). There were
many specific mutations attributed to each
subgenotype of EV-71 and CV-A16. No
mutation was found in EV-71 VP4, while one
mutation, I61M was seen in VP4 of isolates
from subgenotype B2c (Figure 5g). Many
mutations were observed in VP1 of Malaysian
EV-71 (16 mutations) and CV-A16 (29
mutations) (Figure 5a-5c). For EV-71, six
mutations were due to differences with the
prototype BrCr virus (genotype A), while in
CV-A16, there were 26 mutations contributed
by differences with prototype CV-A16/G10
(genotype A). Both EV-71 and CV-A16 have
similar mutations at positions 22, 43 and 240.
For 3D, EV-71 and CV-A16 have 12 and 16
mutations, respectively, and five similarities
at positions 368, 370, 383, 396 and 410 were
Figure 2. Phylogenetic tree of EV-71 VP1. The tree was drawn using partial VP1 gene sequences from
this study (?) and also other Malaysian sequences available in GenBank. The tree was outgrouped
with CV-A16/G10. All the subgenotypes and years of isolation of Malaysian isolates are labeled
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Figure 3. Phylogenetic trees of CV-A16 VP4 and VP1. The trees were drawn using VP4 and VP1 gene
sequences from this study (Δ) and also other Malaysian sequences available in GenBank. The tree was
outgrouped with EV-71 BrCr. All the subgenotypes and years of isolation of Malaysian isolates are
labeled
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shared (Figure 5d-f). These common sites for
mutations showed that these amino acids
were hot spots for mutations to occur.
Recently, the crystal structure of EV-71
capsid was elucidated (Wang et al., 2012;
Plevka et al., 2012). Based on that, two
observed amino acids changes in VP1 of
EV-71, positions 98 and 184, were located
at the immunogenic BC loop and FG loop,
respectively (Figure 5b). More VP1 amino
acid changes of CV-A16 were located at the
immunogenic regions, position 101 in the
BC loop, 183 in the FG loop, and positions
213, 215, 217 and 220 in the GH loop
Figure 4. Phylogenetic tree of EV-71 and CV-A16 3D. The tree was drawn using partial 3D gene sequences
of 306 bp. 3D sequences of EV-71 (?) and CV-A16 (Δ) from this study were compared with other HEV-
A sequences available in GenBank. The tree was mid-point rooted. All the subgenotypes and years of
isolation of Malaysian isolates are labeled. The three recombinant B3 isolates are underlined in black
Table 3. Comparison of nucleotide and amino
acid similarities of EV-71 and CV-A16 sequenced
in the present study
Similarity VP4 (%) VP1 (%) 3D (%)
EV71
Nucleotide 78-100 80-100 73-100
Amino acid 89-100 89-100 93-100
CV-A16
Nucleotide 87-100 88-100 91-100
Amino acid 98-100 97-100 96-100
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(Figure 5b). There were five amino acid
differences between EV-71 and CV-A16 in
the neutralization epitopes (209-220), which
suggested that both EV-71 and CV-A16 have
specific neutralization epitopes (Figure 5b).
Selective pressures on EV-71 and CV-A16
genes
It was of interest to understand the type of
selective pressures acting on the Malaysian
EV-71 and CV-A16 genes. No positive
selection was detected. In EV-71 VP4, partial
VP1 and partial 3D, 39% (29/69), 32.5% (89/
274) and 53.7% (101/188) of the amino acids
were under purifying selection, respectively.
In CV-A16, VP4, VP1 and partial 3D, only 2.9%
(2/69), 4.7% (14/297) and 7.6% (18/236) of the
amino acids were under purifying selection,
respectively. EV-71 showed strong purifying
selection in all the three genes as compared
to CV-A16.
DISCUSSION
The present study was aimed at integrating
the molecular epidemiological information
known about EV-71 and CV-A16 in Malaysia.
Malaysia has experienced at least five HFMD
outbreaks in the last ten years. Major fatal
HFMD outbreaks occurred in 1997 and 2000,
and were caused by EV-71. Other outbreaks
occurred in 2003, 2006 and 2008/2009
(reviewed in Chan et al., 2011; Podin et al.,
2006). Like many other studies, we found
no associations between subgenotype and
clinical severity (reviewed in Chan et al.,
2011). However, this could also be due to the
Figure 5. Genetic changes in EV-71 and CV-A16. Comparison of VP1 amino acid changes of CV-A16 (a)
and EV-71 (c), and the graphical representation of VP1 showing the antigenic domains, neutralization
epitopes and location of mutations (b). Comparison of 3D amino acid changes of CV-A16 (d) and EV-
71 (e), and the graphical representation of 3D showing the functional domains and location of mutations
(f). A single CV-A16 VP4 amino acid change was in position 21 (g). No amino acid changes were found
in EV-71 at VP4 gene region. The solid lines represent mutations observed in CV-A16 and the dotted
lines are mutations observed in EV-71. Amino acid changes observed in the present study are underlined
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small number of fatal and severe EV-71 cases
in this study.
Three genomic regions, VP4, VP1 and
3D were chosen for sequencing to provide
further data on evolution of the viruses. VP4
is usually buried within and not likely to be
under immune pressure. Interestingly, no
amino acid mutations were observed in EV-
71 and there was only one mutation in CV-
A16. This highlights the importance of the
functionally conserved VP4 for uncoating.
VP1 is the most immunodominant protein
and always under high immune selection.
This study showed that many of the mutations
were located at the loops that are highly
immunogenic. 3D is the viral RNA
polymerase, which is functionally conserved
and provides evidence of recombination. In
the 3D, the mutations were mainly located at
the finger subdomain, palm motif C and D. It
is likely that mutations alone may not be
sufficient to confer different virulence, which
may also be dependent on host factors and
immune response.
VP1 and VP4 are the most commonly
used gene regions for genotyping. We have
previously showed that both VP1 and 3D
phylogenies provided more accurate
genotyping which better reflects genotyping
with complete genomes, as compared to VP4
(Chan et al., 2010). We have also observed
that some isolates in VP4 were not clustered
according to their genotypes as identified by
VP1 in the present study.
Many EV-71 subgenotypes circulating
worldwide are not present in Malaysia. After
2003, the circulating subgenotypes were
C1 and C2 in Europe, C1, C2, C4/D and C5
in Thailand and C4/D in China (Chan et al.,
2011). China has recently reported the
presence of subgenotype C2 at low levels
(Tao et al., 2012). Japan has reported frequent
importations and exportations of EV-71 to and
from neighbouring countries (Mizuta et al.,
2005). We only observed the presence of
subgenotypes C5 and C4/D from a few
previously sequenced isolates. This suggests
that importation or exportation of our
Malaysian isolates to/from other countries
were not common or present at very low
levels. A similar phenomenon was observed
with CV-A16. Subgenotype B2c seen in
Malaysia was not observed in China (Li et
al., 2005; Zhang et al., 2010; Zong et al.,
2011).
It is unclear why there were many
subgenotypes of EV-71 circulating in 1997,
but later only subgenotype B5 emerged to
become the sole currently circulating virus.
The persistence of subgenotype B5 may be
due to the presence of high levels of
population immunity towards the previous
genotypes. In contrast, Taiwan demonstrated
many episodes of genotype displacements,
from B1 in 1986, C2 in 1998, B4 in 2000 and
2001, C4 in 2004 and 2005, and finally B5
in 2008. Huang and colleagues (2009)
used antigenic cartography mapping to
demonstrate that subgenotype B5 was
antigenically distinct from subgenotype
B4 and C. The mechanism of genotype
displacement may be due to low
neutralization antibody levels against the
new antigenic variant in that population.
Recombination is common in
enteroviruses (Santti et al., 1999) and has
been reported in EV-71 and CV-A16 (Yoke-
Fun & Abu Bakar, 2006; Zhao et al., 2011). As
in our previously published study, we have
observed recombination in EV-71 isolates
from subgenotype B3 (Yoke-Fun & Abu Bakar,
2006). These isolates clustered together with
prototype CV-A16/G10 in the 3D region. This
seems to correlate with our previous findings
that all the current genotypes have emerged
sometime ago through recombination with
other prototype HEV-A. Apart from EV-71
subgenotype B3, no other EV-71 or CV-A16
isolates showed significant incongruence
in the phylogeny. This may imply that
recombination only plays a minor role in
generating the genetic diversity in the
circulating EV-71 and CV-A16. However,
recombination that drives the diversification
of EV-71 may actually render the virus less
fit. Subgenotype B3 was only isolated in
1997 and not seen after that. We have also
previously showed that recombinant B3
was less virulent in mice (Chan & Abu Bakar,
2005).
Genetic diversity serves as a way for
viruses to adapt to changing environments.
High genetic diversity was observed in the
Malaysian EV-71, but diversity was lower in
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CV-A16. High genetic diversity in EV-71 may
allow the virus to increase fitness and evade
host immune response. Low genetic diversity
in CV-A16 may correlate with the low
mutation rates. The average evolutionary rate
of CV-A16 was only 0.91 X 10-2 nucleotide
substitutions per year, compared to a rate of
1.35 X 10-2 in EV-71 (Brown et al., 1998;
Zhang et al., 2010). In this study, the major
driver of diversification for EV-71 and CV-A16
is likely to be purifying selection. Strong
purifying selective pressures were observed
in EV-71 but less so in CV-A16. CV-A16 has
undergone very few amino acid changes, and
very few sites were under purifying selection.
As a consequence of the strong purifying
selection, EV-71 subgenotypes B3 and C2
disappeared after the 1997 outbreak, and
were followed by B4 and C1 later. Hence,
purifying selection has resulted in extinction
of these less-adapted variants. Strong
purifying selection has also been found in
human rhinovirus (Kristler et al., 2007) and
foot, mouth and disease virus (Carillo et al.,
2005).  In both viruses, the purifying selection
was strongest in 3D as this gene needs to be
functionally conserved for virus replication.
There are some limitations in our study.
Occurrence of recombination was not
common in EV-71 and not obvious in CV-A16.
This could be due to the short gene regions
used. It was previously reported that
recombination breakpoints occurred at
the 2B gene region (Huang et al., 2008; Zhao
et al., 2011), which was not sequenced in
the study. Hence, the elucidation of
recombination is best performed with the
complete genome. We did not sequence all
the isolates from the study period due to lack
of funding, and may have missed isolates from
some genotypes. We would also have missed
very mild cases who did not attend the
hospital. Nonetheless, our present study has
helped us to understand the genetic diversity
and evolutionary forces acting on VP4, VP1
and 3D of EV-71 and CV-A16 in Malaysia.
With all the ongoing vaccine trials in
Singapore, China and Taiwan, it is important
to monitor the genetic mutations that may lead
to antigenic changes and emergence of new
subgenotypes in these two viruses.
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